NCT05177497 is a phase 2, open-label, single arm study investigating SHR-1701, a novel bifunctional fusion protein composed of a mAb against PD-L1 fused with the extracellular domain of TGF-β receptor II, as a consolidation strategy in inoperable stage III NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.